March 5, 2018

Clearside Biomedical Announces Positive Topline Results from Pivotal Phase 3 Clinical Trial of CLS-TA

Clearside Biomedical (NASDAQ:CLSD), a late-stage biopharmaceutical company developing first-in-class drug therapies to treat back-of-the-eye diseases, today announced positive topline results...
April 20, 2017

Clearside Biomedical Completes Enrollment for Phase 1/2 Trial

Clearside Biomedical has finalized the enrollment for its clinical trial of CLS-TA in treating diabetic macular edema.